Bowel Cancer Prehab: Strength & Recovery Program

The landscape of cancer care in Aotearoa New Zealand is shifting, moving proactively towards ‘prehabilitation’ – optimizing a patient’s health *before* treatment begins. This isn’t simply about feeling better; emerging evidence suggests prehabilitation can significantly improve treatment outcomes, reduce side effects, and enhance quality of life. A $1 million investment from the Cancer Society, including a PhD scholarship for bowel cancer survivor Jodie Collins, signals a growing national commitment to this patient-centered approach.

The Rise of Prehabilitation: A Necessary Evolution

For decades, cancer treatment has largely been reactive – addressing the disease *after* diagnosis. However, research increasingly demonstrates that a patient’s physical and mental condition significantly impacts their ability to tolerate and respond to treatment. Prehabilitation aims to build resilience *before* the onslaught of chemotherapy, surgery, or radiation. Collins’ personal experience, coupled with her academic background in sport and exercise science, uniquely positions her to address this need. Her story – navigating a late diagnosis, a family history of the disease, and multiple surgeries – underscores the urgency and importance of empowering patients to take control of their health journey.

The Cancer Society’s investment isn’t isolated. Globally, there’s a growing recognition of the value of prehabilitation. However, implementation remains uneven. New Zealand faces unique challenges, including geographical disparities in access to healthcare and a need for culturally appropriate programs. Collins’ focus on “underserved communities” and creating a program that “works for people where they are at” is therefore critical.

Beyond Bowel Cancer: A Ripple Effect

While Collins’ initial research focuses on bowel cancer, the principles of prehabilitation are applicable across a wide range of cancer types. The other projects funded by the Cancer Society – developing a DNA-capture device for early cancer detection (Otago), investigating growth hormone blockers for melanoma (Auckland), and new treatments for NRAS-mutated melanomas (Auckland), and improving H. pylori treatment efficiency (Otago) – all contribute to a more comprehensive and proactive approach to cancer care. Dr. Jolly’s statement highlights the Cancer Society’s long-term commitment to building a robust cancer research workforce, essential for sustained innovation.

The Forward Look: What to Watch

The next 12-18 months will be crucial. Collins will begin her PhD at Auckland University, initiating the program development phase. Key milestones will include patient recruitment, program design, and initial data collection. Expect to see a growing emphasis on patient-reported outcomes – measuring not just survival rates, but also quality of life, functional capacity, and emotional wellbeing.

Furthermore, watch for increased advocacy for the integration of prehabilitation into standard cancer care pathways. The success of Collins’ program could serve as a model for other cancer types and regions, potentially leading to policy changes and increased funding for prehabilitation services nationwide. The challenge will be scaling these programs effectively and ensuring equitable access for all New Zealanders, regardless of location or socioeconomic status. The focus on making research “patient friendly,” as championed by Collins through her advisory panel role, will be paramount to achieving this goal.